Skip to main content
Erschienen in: Obesity Surgery 10/2018

24.04.2018 | Original Contributions

Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up

verfasst von: Zhigao Song, Xiaojian Dai, Hao Yu, Qing Luo, Hongbin Zhang, Liangping Wu

Erschienen in: Obesity Surgery | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to measure changes of insulin-like growth factor binding protein-1 (IGFBP-1) in patients with type 2 diabetes mellitus (T2D) following gastric bypass surgery.

Methods

A total of 10 patients with T2D underwent laparoscopic Roux-en-Y gastric bypass (RYGB) surgery. Patient height, weight, waist circumference, and hip circumference were measured pre- and post-operatively at 6 months after surgery. Serum samples were collected at 6 months after surgery to determine fasting blood glucose, glycosylated Hb, fasting insulin, C-peptide, and 2-h postprandial blood glucose, insulin, and C-peptide. Serum was collected at 3 days and 6 months after surgery and IGFBP-1 level determined using ELISA. Serum samples were also collected from 30 healthy weight subjects and 27 overweight control subjects.

Results

Body weight, BMI, and waist circumference were significantly improved following RYGB surgery. Blood glucose, fasting blood glucose, 2-h postprandial blood glucose, and HbA1c were also significantly improved. Fasting C-peptide and 2-h postprandial C-peptide were non-significantly reduced. Serum IGFBP-1 significantly increased at 3 days and 6 months after RYGB surgery. Pre-operative serum IGFBP-1 was not significantly different from healthy weight subjects or overweight subjects.

Conclusion

Increased serum level of IGF-binding proteins after RYGB in 6 months is increased post-surgery compared with overweight and healthy weight controls. IGFBP-1 may serve as part of new supplementary criteria for surgical selection and for defining the success of RYGB.
Literatur
1.
Zurück zum Zitat Unnikrishnan R, Pradeepa R, Joshi SR, et al. Type 2 diabetes: demystifying the global epidemic. Diabetes. 2017;66:1432–42.CrossRefPubMed Unnikrishnan R, Pradeepa R, Joshi SR, et al. Type 2 diabetes: demystifying the global epidemic. Diabetes. 2017;66:1432–42.CrossRefPubMed
2.
Zurück zum Zitat Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–350–50-352.CrossRef Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–350–50-352.CrossRef
3.
Zurück zum Zitat Hjortebjerg R, Laugesen E, Hoyem P, et al. The IGF system in patients with type 2 diabetes: associations with markers of cardiovascular target organ damage. Eur J Endocrinol. 2017;176:521–31.CrossRefPubMed Hjortebjerg R, Laugesen E, Hoyem P, et al. The IGF system in patients with type 2 diabetes: associations with markers of cardiovascular target organ damage. Eur J Endocrinol. 2017;176:521–31.CrossRefPubMed
4.
Zurück zum Zitat Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009;25:3–12.CrossRefPubMedPubMedCentral Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009;25:3–12.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314–22.CrossRefPubMed Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314–22.CrossRefPubMed
6.
Zurück zum Zitat Payne JF, Tangpricha V, Cleveland J, et al. Serum insulin-like growth factor-I in diabetic retinopathy. Mol Vis. 2011;17:2318–24.PubMedPubMedCentral Payne JF, Tangpricha V, Cleveland J, et al. Serum insulin-like growth factor-I in diabetic retinopathy. Mol Vis. 2011;17:2318–24.PubMedPubMedCentral
7.
Zurück zum Zitat Urakami T, Kubota S, Nitadori Y, et al. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28:1876–81.CrossRefPubMed Urakami T, Kubota S, Nitadori Y, et al. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28:1876–81.CrossRefPubMed
8.
Zurück zum Zitat Song X, Teng J, Wang A, et al. Positive correlation between serum IGF-1 and HDL-C in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;118:44–9.CrossRefPubMed Song X, Teng J, Wang A, et al. Positive correlation between serum IGF-1 and HDL-C in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;118:44–9.CrossRefPubMed
10.
Zurück zum Zitat Brynskov T, Laugesen CS, Floyd AK, et al. The IGF-Axis and diabetic retinopathy before and after gastric bypass surgery. Obes Surg. 2017;27:408–15.CrossRefPubMed Brynskov T, Laugesen CS, Floyd AK, et al. The IGF-Axis and diabetic retinopathy before and after gastric bypass surgery. Obes Surg. 2017;27:408–15.CrossRefPubMed
11.
12.
Zurück zum Zitat Smeu B, Balescu I, Sarbu A, et al. Early improvement in glycemic metabolism after laparoscopic sleeve gastrectomy in obese patients - a prospective study. Chirurgia (Bucur). 2015;110:430–9. Smeu B, Balescu I, Sarbu A, et al. Early improvement in glycemic metabolism after laparoscopic sleeve gastrectomy in obese patients - a prospective study. Chirurgia (Bucur). 2015;110:430–9.
13.
Zurück zum Zitat Raverdy V, Baud G, Pigeyre M, et al. Incidence and predictive factors of postprandial Hyperinsulinemic hypoglycemia after roux-en-Y gastric bypass: a five year longitudinal study. Ann Surg. 2016;264:878–85.CrossRefPubMed Raverdy V, Baud G, Pigeyre M, et al. Incidence and predictive factors of postprandial Hyperinsulinemic hypoglycemia after roux-en-Y gastric bypass: a five year longitudinal study. Ann Surg. 2016;264:878–85.CrossRefPubMed
14.
Zurück zum Zitat Moses AC, Young SC, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45:91–100.CrossRefPubMed Moses AC, Young SC, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45:91–100.CrossRefPubMed
15.
Zurück zum Zitat Haywood NJ, Cordell PA, Tang KY, et al. Insulin-like growth factor binding protein 1 could improve glucose regulation and insulin sensitivity through its RGD domain. Diabetes. 2017;66:287–99.CrossRefPubMed Haywood NJ, Cordell PA, Tang KY, et al. Insulin-like growth factor binding protein 1 could improve glucose regulation and insulin sensitivity through its RGD domain. Diabetes. 2017;66:287–99.CrossRefPubMed
16.
Zurück zum Zitat Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology. 2003;144:3922–33.CrossRefPubMed Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology. 2003;144:3922–33.CrossRefPubMed
17.
Zurück zum Zitat Laager R, Keller U. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1993;36:966–71.CrossRefPubMed Laager R, Keller U. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1993;36:966–71.CrossRefPubMed
18.
Zurück zum Zitat Lee PD, Lustig RH, Lenders C, et al. Insulin-like growth factor binding protein 1 predicts insulin sensitivity and insulin area-under-the-curve in obese, nondiabetic adolescents. Endocr Pract. 2016;22:136–42.CrossRefPubMed Lee PD, Lustig RH, Lenders C, et al. Insulin-like growth factor binding protein 1 predicts insulin sensitivity and insulin area-under-the-curve in obese, nondiabetic adolescents. Endocr Pract. 2016;22:136–42.CrossRefPubMed
19.
Zurück zum Zitat Aneke-Nash CS, Parrinello CM, Rajpathak SN, et al. Changes in insulin-like growth factor-I and its binding proteins are associated with diabetes mellitus in older adults. J Am Geriatr Soc. 2015;63:902–9.CrossRefPubMed Aneke-Nash CS, Parrinello CM, Rajpathak SN, et al. Changes in insulin-like growth factor-I and its binding proteins are associated with diabetes mellitus in older adults. J Am Geriatr Soc. 2015;63:902–9.CrossRefPubMed
20.
Zurück zum Zitat Gokulakrishnan K, Velmurugan K, Ganesan S, et al. Circulating levels of insulin-like growth factor binding protein-1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai urban rural epidemiology study 118). Metabolism. 2012;61:43–6.CrossRefPubMed Gokulakrishnan K, Velmurugan K, Ganesan S, et al. Circulating levels of insulin-like growth factor binding protein-1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai urban rural epidemiology study 118). Metabolism. 2012;61:43–6.CrossRefPubMed
21.
Zurück zum Zitat Hjortebjerg R, Flyvbjerg A, Frystyk J. Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes. Expert Opin Ther Targets. 2014;18:209–24.CrossRefPubMed Hjortebjerg R, Flyvbjerg A, Frystyk J. Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes. Expert Opin Ther Targets. 2014;18:209–24.CrossRefPubMed
22.
Zurück zum Zitat Matsui H, Musicki B, Sopko NA, et al. Early-stage type 2 diabetes mellitus impairs erectile function and neurite outgrowth from the major pelvic ganglion and downregulates the gene expression of neurotrophic factors. Urology. 2017;99:281–7.CrossRef Matsui H, Musicki B, Sopko NA, et al. Early-stage type 2 diabetes mellitus impairs erectile function and neurite outgrowth from the major pelvic ganglion and downregulates the gene expression of neurotrophic factors. Urology. 2017;99:281–7.CrossRef
23.
Zurück zum Zitat Luo J, Murphy LJ. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol. 1992;8:155–63.CrossRefPubMed Luo J, Murphy LJ. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol. 1992;8:155–63.CrossRefPubMed
24.
Zurück zum Zitat Katz LE, DeLeon DD, Zhao H, et al. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab. 2002;87:2978–83.CrossRefPubMed Katz LE, DeLeon DD, Zhao H, et al. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab. 2002;87:2978–83.CrossRefPubMed
25.
Zurück zum Zitat Matsumoto T, Ishida K, Nakayama N, et al. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol. 2009;296:H1388–97.CrossRefPubMed Matsumoto T, Ishida K, Nakayama N, et al. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol. 2009;296:H1388–97.CrossRefPubMed
26.
Zurück zum Zitat Farey JE, Fisher OM, Levert-Mignon AJ, et al. Decreased levels of circulating Cancer-associated protein biomarkers following bariatric surgery. Obes Surg. 2017;27:578–85.CrossRefPubMed Farey JE, Fisher OM, Levert-Mignon AJ, et al. Decreased levels of circulating Cancer-associated protein biomarkers following bariatric surgery. Obes Surg. 2017;27:578–85.CrossRefPubMed
27.
Zurück zum Zitat Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002;175:19–31.CrossRefPubMed Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002;175:19–31.CrossRefPubMed
28.
Zurück zum Zitat Sabater M, Moreno-Navarrete JM, Ortega FJ, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab. 2010;95:4720–8.CrossRefPubMed Sabater M, Moreno-Navarrete JM, Ortega FJ, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab. 2010;95:4720–8.CrossRefPubMed
29.
Zurück zum Zitat Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes. 2012;36:1442–9.CrossRef Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes. 2012;36:1442–9.CrossRef
30.
Zurück zum Zitat Kim KE, Cho YS, Baek KS, et al. Lipopolysaccharide-binding protein plasma levels as a biomarker of obesity-related insulin resistance in adolescents. Korean J Pediatr. 2016;59:231–8.CrossRefPubMedPubMedCentral Kim KE, Cho YS, Baek KS, et al. Lipopolysaccharide-binding protein plasma levels as a biomarker of obesity-related insulin resistance in adolescents. Korean J Pediatr. 2016;59:231–8.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Fruhbeck G, Gomez-Ambrosi J. Rationale for the existence of additional adipostatic hormones. FASEB J. 2001;15:1996–2006.CrossRefPubMed Fruhbeck G, Gomez-Ambrosi J. Rationale for the existence of additional adipostatic hormones. FASEB J. 2001;15:1996–2006.CrossRefPubMed
32.
Zurück zum Zitat Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–13.CrossRefPubMed Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–13.CrossRefPubMed
33.
Zurück zum Zitat Liver GC. Asprosin - new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016;12:312. Liver GC. Asprosin - new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016;12:312.
34.
Zurück zum Zitat Fruhbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11:465–77.CrossRefPubMed Fruhbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11:465–77.CrossRefPubMed
Metadaten
Titel
Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up
verfasst von
Zhigao Song
Xiaojian Dai
Hao Yu
Qing Luo
Hongbin Zhang
Liangping Wu
Publikationsdatum
24.04.2018
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 10/2018
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3242-8

Weitere Artikel der Ausgabe 10/2018

Obesity Surgery 10/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.